Introduction
============

Multiple myeloma (MM) is characterized by malignant plasma cell proliferation in the bone marrow (BM) associated with monoclonal protein in the serum and/or urine.[@b1-ott-8-2805],[@b2-ott-8-2805] Hematopoietic stem cell transplantation and novel agents such as bortezomib, thalidomide, and lenalidomide have improved the survival of MM patients.[@b3-ott-8-2805],[@b4-ott-8-2805] However, most patients eventually relapse even after the achievement of a complete therapeutic response. Improvements in molecular profiling technologies have provided new insight into the basic molecular events underlying the development of MM as well as the mechanisms of anticancer drug resistance. The transition from the long-established one-size-fits-all approach to new strategies based on individual genetic profiles provides an opportunity to transform current diagnostics into individual prognostic and even predictive classifications.

In MM, there are two distinct genetic subtypes based on copy number alterations and translocations. Approximately half of all MM cases are hyperdiploid, which is characterized by multiple trisomies of chromosomes 3, 5, 7, 9 11, 15, 19, and 21 and a lower prevalence of primary translocations involving the immunoglobulin heavy chain (IgH) locus at 14q32.[@b5-ott-8-2805],[@b6-ott-8-2805] The remaining cases form the nonhyperdiploid group, and chromosomes 8, 13, 14, and 16 are frequently lost. Nonhyperdiploid myeloma is strongly associated with translocations of IgH alleles with various partner chromosomes. Copy number alterations in chromosomal regions, such as 1q, 6q, 8p, and 16q, occur in both subtypes. Overall, nonhyperdiploid MM is associated with worse survival compared with hyperdiploid MM.

Methods for determining DNA content and, ultimately, ploidy in MM include conventional cytogenetics, fluorescence in situ hybridization (FISH), comparative genomic hybridization, and, recently, massively parallel whole genome sequencing. Because unique mutations have been observed in individual human cancer samples, the identification and characterization of the molecular alterations of individual cancer patients is a critical step toward the development of more effective personalized therapies. For example, next-generation sequencing (NGS) technologies have revolutionized cancer genomics research by providing a comprehensive method of detecting genomic alterations associated with somatic cancer.[@b7-ott-8-2805]--[@b9-ott-8-2805] In this study, we sequenced all exons of 409 cancer-related genes in matched tumor and normal DNA samples from a multidrug-resistant myeloma patient using a next-generation semiconductor sequencing protocol.

Case report
===========

A 69-year-old male presented in October 2010 with back pain. Physical examination and magnetic resonance imaging revealed large focal lesions in the fourth thoracic vertebra ([Figure 1A](#f1-ott-8-2805){ref-type="fig"}) and first lumbar vertebra ([Figure 1B](#f1-ott-8-2805){ref-type="fig"}). Laboratory evaluation revealed a white blood cell count of 2.5×10^3^/μL with no atypical cells, a red blood cell count of 3.67×10^6^/μL, a hemoglobin level of 11.6 g/dL, and a platelet count of 122×10^6^/μL. The serum total protein level was 10.7 g/dL, the albumin level was 3.4 g/dL, the serum β2 microglobulin level was 4.2 mg/dL, and the serum calcium level was 8.9 mg/dL. The concentrations of IgG, IgA, and IgM were 6,284, 34, and 25 mg/dL, respectively. The monoclonal protein IgG was increased, and serum immunofixation revealed the production of IgG with λ light-chain restriction (data not shown). The proliferation of plasma cells (more than 10% among all nucleated cells) was also detected in BM aspirates. When BM biopsy was performed, the infiltration of plasma cells expressing IgG λ monoclonal protein was identified by pathological investigation, and the patient was diagnosed with MM (Stage II according to the International Staging System). Chromosome analysis at this time using conventional Giemsa banding of BM-derived metaphase spreads revealed a normal karyotype (46, XX) in all analyzed cells. The patient was then treated with one cycle of high-dose dexamethasone, followed by three cycles of bortezomib plus dexamethasone. He achieved complete response according to the International Myeloma Working Group uniform response criteria. His symptoms were also significantly improved.

In August 2012, the serum concentrations of IgG and free light chain (FLC) gradually increased, suggesting the worsening of his MM. His complete blood count was as follows: 1.8×10^3^/μL white blood cells, 3.61×10^6^/μL red blood cells, 11.6 g/dL hemoglobin, and 55×10^6^/μL platelets. BM analysis showed complex aberrations often observed in this patient ([Figures 2A](#f2-ott-8-2805){ref-type="fig"} and [2B](#f2-ott-8-2805){ref-type="fig"}) and an elevated plasma cell percentage (59.8%). His karyotype was 39, XY, del(1)(p22p36), −3, −6, der(8)t(6:8)(p11.1:p23), −10, t(11:14)(q13:q32), −12, add(13) (q22), add(16)(q22), −17, add(18)(p11), −19, −20, +mar \[4\]/46, XY \[20\]. The chromosomal translocation t(11:14) (q13:q32), which generates the IgH/CCND1 fusion gene, was also identified in our case by FISH ([Figure 2C](#f2-ott-8-2805){ref-type="fig"}).

The patient was started on a bortezomib, cyclophosphamide, and dexamethasone regimen. No serious complications occurred during the course of the treatment, and a partial response was observed with a decrease in the serum FLC value. After seven cycles of this regimen, however, his condition progressively deteriorated, with increases in serum lambda immunoglobulin light chain and LDH, a deterioration of renal function, and the appearance of circulating plasma cells in the peripheral blood (up to 5% of the total peripheral leukocyte population). He was admitted for combination chemotherapy with combination chemotherapy with bortezomib, cyclophosphamide, lenalidomide, and dexamethasone, but his response was poor ([Figure 3](#f3-ott-8-2805){ref-type="fig"}), and an increase in myeloma cells was detected by BM biopsy. Unfortunately, the patient has since passed away, and his family did not choose to perform postmortem examination.

The patient provided consent for use of his medical record and samples for clinical and research purposes, and the examination was performed in accordance with the Declaration of Helsinki. The sequence study was approved by the Institutional Review Boards of Sapporo Medical University. Retrospectively, to better understand the molecular pathogenesis in this patient, we sequenced 409 cancer-related genes in matched tumor and nontumor DNA samples at relapse in August 2012 using an Ion Torrent PGM (Life Technologies, Carlsbad, CA, USA). DNA was extracted from magnetic bead--enriched BM CD138 positive tumor cells from the patient, and CD138 negative cells were used as matched nontumor cells. DNA (40 ng) was used for multiplex polymerase chain reaction (PCR) amplification with an Ion Ampliseq Comprehensive Cancer Panel (Life Technologies), enabling the targeted coverage of all exons of 409 cancer-related genes frequently cited and mutated (covered regions =95.4% of total). The 15,992 amplicons obtained represented more than 1.2 Mb of target sequence. Library preparation and sequencing with an Ion Torrent PGM was performed as previously described.[@b9-ott-8-2805] The mean read depths were 125× (tumor) and 152× (normal). Alignment to the human genome build 19 and variant calling were performed by Ion Reporter Software 4.0. Mutations were also validated by conventional Sanger sequencing. We identified eight nonsynonymous somatic mutations (6.49 mutations/Mb; [Table 1](#t1-ott-8-2805){ref-type="table"}). We included missense mutations in seven genes (SYNE1, IKBKB, ERBB3, MYH11, CYLD, TP53, and CDH2) and a frameshift mutation in EGFR. Changes in relative copy number were also assessed from the sequencing data, and we identified 133 copy number variant (CNV) regions, including 87 gain and 46 loss regions ([Figure 2B](#f2-ott-8-2805){ref-type="fig"} and [Table S1](#SD1-ott-8-2805){ref-type="supplementary-material"}). Importantly, we found a gain in the copy number of CCND1, a gene encoding cyclin D1. To check the contamination of tumor cells in the CD138 negative subset, we compared CD138 negative DNA of this patient and peripheral blood DNA from two healthy donors. We found single nucleotide variants in the CD138 negative DNA of this patient; however, all variants had previously been reported in the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP/>) ([Tables 2](#t2-ott-8-2805){ref-type="table"} and [3](#t3-ott-8-2805){ref-type="table"}). Therefore, we can rule out tumor cell contamination in the CD138 negative subset.

Discussion
==========

MM is a plasma cell malignancy characterized by a heterogeneous clinical course. Treatments for MM have remarkably improved in recent years, due in part to the introduction of novel therapies such as bortezomib, thalidomide, and lenalidomide. Despite these advancements, the prognosis of patients with relapse and refractory MM remains poor, and novel therapies are needed. Alternatively, the identification of novel targets or signaling pathways regulating myeloma cell proliferation would improve the clinical outcome and survival of refractory MM patients. Several pathways related to drug resistance and cell survival, such as Notch1, Akt, and NF-κB, are activated to protect MM cells from death.[@b10-ott-8-2805]--[@b12-ott-8-2805] Here, we describe the characterization of genetic abnormalities found in myeloma cells in a patient with refractory MM.

In nonhyperdiploid MM, the IgH gene (14q32) commonly fuses with FGFR3 (4p16), MMSET (4p16.3), CCND3 (6p21), CCND1 (11q13), and MAF (16q23), resulting in the direct or indirect dysregulation of cyclin D.[@b13-ott-8-2805] Among the nonhyperdiploid myelomas, the hypodiploid subtype (≦44 chromosomes) has the most aggressive clinical phenotype, but the genetic differences between the groups have not been completely defined. Cytogenetic analysis revealed that this patient had a hypodiploid karyotype with 39 chromosomes and complex chromosomal abnormalities, including t(11:14) (q13:q32). CCND1 expression is generally related to copy number aberrations. Although we did not analyze CCND1 mRNA expression, CNV analysis revealed a gain of 11q13--q21, suggesting the presence of cyclin D1 dysregulation.

Several NGS platforms are available for the sequencing of targeted genomic regions to analyze a variety of disease-associated changes, such as point mutations, insertions, deletions, and CNVs. CNV analysis of the sequencing data revealed that this patient had diverse DNA copy number alterations, including large and regional gains and losses ([Figure 2B](#f2-ott-8-2805){ref-type="fig"} and [Table S1](#SD1-ott-8-2805){ref-type="supplementary-material"}). Additionally, we detected eight somatic mutations among 409 cancer-related genes ([Table 1](#t1-ott-8-2805){ref-type="table"}). We considered gene sets based on existing insights into the biology of this MM patient. It has been proposed that activation of the NF-kB pathway is important in the pathogenesis of MM, as well as in resistance to chemotherapy. We observed two point mutations and three CNVs affecting NF-κB pathway genes, including IKBKB, CYLD, IKBKE, CD79B, and SYK ([Tables 1](#t1-ott-8-2805){ref-type="table"} and S1). Although additional experiments are required to establish the functional significance of genetic alterations of these genes in MM cells, NF-κB pathway activation may be involved in the molecular pathogenesis of this patient's disease.

Alterations in the tumor suppressor retinoblastoma (RB) and p53 or their respective pathways are frequently observed in human cancers.[@b14-ott-8-2805] In MM, a deletion or mutation of p53 (17p13) or RB1 (13q14.2) is considered to be predictive of poor prognosis. We found a monoallelic chromosome 17 deletion and a missense mutation in the DNA-binding domain of p53 (Arg158Gly), suggesting the abrogation of p53 transcription. Moreover, the deletion of the CNV in 13q14.2 was detected in this patient, resulting in the inactivation of two key regulators of the cell cycle, RB1 and p53.

A recent study has described an increased rate of mutations in receptor tyrosine kinases (RTKs) and their associated signaling effectors, pointing to a more potent role of this pathway in MM than was previously appreciated.[@b15-ott-8-2805] We found two mutations in RTKs, including a missense mutation in ERBB3 and a truncating mutation in EGFR, and have suggested a role of aberrant RTK signaling in the development or progression of MM in this patient. In addition, few studies have addressed the functional roles of the remaining three mutated genes (SYNE1, MYH11, and CDH2) in myeloma, and further investigations are required. SYNE1 is frequently silenced by DNA methylation in primary cancers of the colon and lung,[@b16-ott-8-2805],[@b17-ott-8-2805] suggesting that a loss of SYNE1 function may be a genetic event that promotes tumor progression. MYH11 is a member of the myosin family, and inversion at the MYH11 locus is found in acute myeloid leukemia.[@b18-ott-8-2805] Additionally, MYH11 mutations have been shown to occur in human colorectal cancers with microsatellite instability.[@b19-ott-8-2805] N-cadherin, encoded by the CDH2 gene, is a transmembrane protein and plays an important role in cell adhesion. Recently, circulating N-cadherin levels was reported to be a negative prognostic factor in patients with MM.[@b20-ott-8-2805] In this study, we performed comprehensive genomic analyses using PCR target enrichment and semiconductor-based sequencing of matched tumor and normal DNA samples obtained from an individual with refractory MM. We detected several genetic alterations that may have been associated with the poor prognosis and poor response to chemotherapy of this patient. Although its value should be further confirmed in larger samples, targeted NGS is considered a valuable tool for high-throughput genetic testing in clinical research.

Supplementary material
======================

  Locus                                   Ploidy   Length (bp)   Gene
  --------------------------------------- -------- ------------- -----------------------------------------------------------------------------------------------
  1p36.31(6531783--6532696)               9        913           PLEKHG5
  1p36.31(6534071--6534252)               9        181           PLEKHG5
  1p36.22(11204731--11317231)             3        112,500       MTOR:MTOR--AS1
  1p33(47685376--47838806)                4        153,430       TAL1:CMPK1
  1p33p13.2(47840544--114940663)          1        67,100,119    CMPK1:CDKN2C:JUN:JAK1:BCL10:LOC646626:DPYD:DPYD--AS1:TRIM33
  1p13.2p12(115006125--120491804)         1        5,485,679     TRIM33:NRAS:NOTCH2
  1q21.1(144882848--144922543)            3        39,695        PDE4DIP
  1q21.1(144922543--144946743)            1        24,200        PDE4DIP
  1q25.3q31.1(185069308--186287597)       1        1,218,289     RNF2:MIR548F1:PRG4:TPR
  1q31.1(186287597--186315401)            3        27,804        MIR548F1:TPR
  1q31.1(186340019--186645716)            6        305,697       MIR548F1:TPR:PTGS2
  1q32.1(204396791--204438963)            3        42,172        PIK3C2B
  1q32.1(204494558--204518660)            1        24,102        MDM4
  1q32.1(204518660--206652476)            4        2,133,816     MDM4:IKBKE
  1q43(237037987--237060883)              5        22,896        MTR
  1q44(243776889--243809266)              0        32,377        AKT3
  2p25.2(5832763--5833155)                10       392           SOX11
  2p25.2p23.3(5833155--24951356)          3        19,118,201    SOX11:MYCN:NCOA1
  2p23.3(24952332--24952686)              0        354           NCOA1
  2p23.3(24962207--25462090)              4        499,883       NCOA1:DNMT3A
  2p21(42509881--47672730)                3        5,162,849     EML4:MSH2
  2p21(47672761--47693939)                0        21,178        MSH2
  2p21(47698056--47705686)                5        7,630         MSH2
  2p16.1p15(61145266--61715462)           1        570,196       REL:XPO1
  2q22.1q22.2(141031958--142888394)       3        1,856,436     LRP1B
  2q22.3(148657078--148657416)            6        338           ACVR2A
  2q31.2q32.2(178096331--190719874)       4        12,623,543    NFE2L2:PMS1
  2q33.1(198263157--198266593)            1        3,436         SF3B1
  2q33.1(198266665--198274567)            5        7,902         SF3B1
  2q33.1q34(198285075--209101941)         4        10,816,866    SF3B1:CREB1:IDH1
  2q35q36.1(216288165--223066804)         3        6,778,639     FN1:STK36:PAX3
  3p26.2p25.2(3192502--12458385)          1        9,265,883     CRBN:FANCD2:C3orf24:VHL:PPARG RAF1:XPC:TGFBR2:MLH1:ITGA9:MYD88:CTNNB1:LTF:SETD2:BAP1: PBRM1:M
  3p25.2p13(12641643--70014401)           1        57,372,758    AGI1:MITF
  3p13(71008300--71015133)                0        6,833         FOXP1
  3p13(71015133--71247590)                1        232,457       FOXP1
  3q22.3q23(138425984--142178221)         4        3,752,237     PIK3CB:FOXL2:ATR
  3q23(142180753--142185454)              10       4,701         ATR
  3q23(142186790--142226819)              4        40,029        ATR
  3q23(142279172--142285045)              4        5,873         ATR
  3q26.32q27.3(178916622--187442712)      3        8,526,090     PIK3CA:SOX2--OT:SOX2:LOC100131635:BCL6
  3q29(195590930--195622288)              3        31,358        TNK2
  4p16.3(1800963--1809006)                3        8,043         FGFR3
  4q12q13.1(55987269--62801812)           4        6,814,543     KDR:LPHN3
  4q13.1(62863973--62935895)              10       71,922        LPHN3
  5q11.2(55259956--55272179)              1        12,223        IL6ST
  5q13.1(67522495--67589174)              4        66,679        PIK3R1
  5q13.1q22.2(67589211--112111335)        1        44,522,124    PIK3R1:APC
  5q22.2(112111335--112176325)            3        64,990        APC
  5q31.1q32(131972888--149514586)         3        17,541,698    RAD50:CTNNA1:CSF1R:PDGFRB
  5q35.3(176683949--180058790)            3        3,374,841     NSD1:FLT4
  6p25.3p22.3(393089--18264237)           5        17,871,148    IRF4:DEK
  6p21.32p21.1(32169809--44219786)        4        12,049,977    NOTCH4:DAXX:PIM1:FOXP4:MIR4641:HSP90AB1
  6p21.1p12.3(44219786--51720789)         3        7,501,003     HSP90AB1:PKHD1
  6p12.3(51720789--51732717)              0        11,928        PKHD1
  6p12.3(51732717--51774287)              5        41,570        PKHD1
  6p12.2(51882320--51909967)              4        27,647        PKHD1
  6p12.2p12.1(52880891--52906053)         7        25,162        ICK
  6p12.1(56371186--56373367)              10       2,181         RNU6--71:DST
  6p12.1(56373367--56418558)              3        45,191        RNU6--71:DST
  6p12.1(56420267--56479190)              4        58,923        RNU6--71:DST
  6p12.1(56489295--56505172)              7        15,877        RNU6--71:DST
  6q12q252(69348493--152749529)           1        83,401,036    BAI3:MAP3K7:EPHA7:PRDM1:FOXO3:ROS1:SGK1:MYB:TNFAIP3:ESR1: SYNE1
  6q25.2(152755037--152762469)            0        7,432         SYNE1
  6q25.2q27(152763208--167275671)         1        14,512,463    SYNE1:IGF2R:RPS6KA2
  7p22.1(6038830--6048682)                6        9,852         PMS2
  7p21.2p112(13978822--55211092)          1        41,232,270    ETV1:IKZF1:EGFR
  7p11.2q212(55211092--91632356)          3        36,421,264    EGFR:LOC100507500:SBDS:AKAP9
  7q22.1(98478735--98491481)              1        12,746        TRRAP
  7q22.1(98491496--98503897)              4        12,401        TRRAP
  7q31.2(116398533--116409750)            1        11,217        MET
  7q31.2q31.33(116409750--126882846)      3        10,473,096    MET:POT1:GRM8
  7q36.1(151873440--151884429)            3        10,989        MLL3
  7q36.1(151884429--151896501)            6        12,072        MLL3
  8p12(30915961--31015061)                1        99,100        WRN
  8p11.21(41801269--41838483)             4        37,214        KAT6A
  8q11.21(48761708--48842433)             3        80,725        PRKDC
  8q11.21(48848199--48848467)             9        268           PRKDC
  8q13.3(71056866--71068855)              4        11,989        NCOA2
  8q22.3(103271231--103284984)            4        13,753        UBR5
  8q22.3(103287769--103288057)            0        288           UBR5
  8q22.3q23.3(103301703--113267690)       3        9,965,987     UBR5:CSMD3
  8q23.3(113275800--113326867)            5        51,067        CSMD3
  8q23.3(113353734--113697671)            4        343,937       CSMD3
  9p24.1(5021975--5055745)                1        33,770        JAK2
  9p24.1(5069115--5080629)                0        11,514        JAK2
  9p24.1p13.2(5080644--37034041)          1        31,953,397    JAK2:PTPRD:PSIP1:CDKN2A:CDKN2B--AS1:CDKN2B:TAF1L:FANCG:PAX5
  9q21.2q22.2(80336237--93607934)         3        13,271,697    GNAQ SYK
  10p12.31(21971114--22019887)            4        48,773        MLLT10
  10p12.31q24.32(22030804--104155714)     1        82,124,910    MLLT10:RET:MAPK8:NCOA4:TET1:KAT6B:BMPR1A:PTEN:ACTA2:FAS:CY P2C19:BLNK:TLX1
  1 0q24.32q26.13(104157967--123353360)   1        19,195,393    NFKB2:SUFU:TCF7L2:FGFR2
  11p15.5p15.4(532629--3714618)           3        3,181,989     HRAS:INS--IGF2:IGF2:NUP98
  11p15.4(3794886--4144704)               1        349,818       NUP98:RRM1
  11p15.4(4147854--4159656)               4        11,802        RRM1
  11q13.1q21(64577195--95712842)          3        31,135,647    MEN1:CCND1:NUMA1:MRE11A:MAML2
  11q21(95826628--96075072)               6        248,444       MAML2:MIR1260B
  11q22.2(102195186--102221298)           3        26,112        BIRC3:BIRC2
  11q22.3(108126821--108202634)           3        75,813        ATM
  11q22.3(108202640--108205758)           8        3,118         ATM
  12p13.32q12(4383139--43825146)          1        39,442,007    CCND2:ING4:ZNF384:KRAS:ADAMTS20
  12q12q24.33(43845982--132562299)        1        88,716,317    ADAMTS20:ARID2:MLL2:ATF1:SMUG1:ERBB3:DDIT3:CDK4:MDM2: PTPN11:HNF1A:HCAR1:EP400
  13q12.13q14.2(26828777--48881526)       1        22,052,749    CDK8:FLT3:FLT1:FOXO1:RB1
  13q14.2(48916694--48955639)             0        38,945        RB1
  13q14.2q34(49027105--113976789)         1        64,949,684    RB1:BIVM--ERCC5:ERCC5:IRS2:LAMP1
  14q32.12(92435944--92470292)            1        34,348        TRIP11
  14q32.2q32.31(99697796--102549592)      4        2,851,796     BCL11B:HSP90AA1
  14q32.31q32.33(102568334--105259056)    4        2,690,722     HSP90AA1:AKT1
  15q14q15.1(39881158--40914530)          3        1,033,372     THBS1:BUB1B:PAK6:CASC5
  15q15.1(40914530--40914946)             8        416           CASC5
  15q15.1q21.3(40915027--57574785)        3        16,659,758    CASC5:LTK:TGM7:TCF12
  15q26.1(91293154--91304549)             4        11,395        BLM
  15q26.1(91306116--91358510)             1        52,394        BLM
  16p13.3(2110598--2110873)               7        275           TSC2
  16p13.3(2126481--2129066)               8        2,585         TSC2
  16p13.3(2129066--3824694)               3        1,695,628     TSC2:CREBBP
  16p12.2(23614957--23646619)             1        31,662        PALB2
  16p12.2p12.1(23646619--27460675)        3        3,814,056     PALB2:IL21R:LOC283888
  16q12.1(50825401--50827575)             0        2,174         CYLD
  16q12.1q24.3(50828113--89882998)        1        39,054,885    CYLD:MMP2:CDH1:CDH5:CDH1:MAF:ZNF276:FANCA
  17p13.2(5405081--5442941)               4        37,860        NLRP1
  17p13.1(8046119--8053735)               5        7,616         PER1
  17p13.1(8108179--8111176)               4        2,997         AURKB
  17p12q11.2(12016465--29663487)          3        17,647,022    MAP2K4:FLCN:NF1
  17q11.2(29663487--29663721)             0        234           NF1
  17q11.2(29663721--29684308)             4        20,587        NF1
  17q23.3q25.3(62008693--75398324)        4        13,389,631    CD79B:PRKAR1A:SEPT9
  17q25.3(78346858--78363051)             3        16,193        RNF213:LOC100294362
  19q13.2(42788861--42799411)             0        10,550        CIC
  19q13.32q13.43(45252220--57746806)      1        12,494,586    BCL3:MARK4:ERCC2:CD3EAP:ERCC1:PPP2R1A:AURKC
  20q12(39708708--40730948)               3        1,022,240     TOP1:PLCG1:PTPRT
  21q22.2q22.3(39947501--46330714)        3        6,383,213     ERG:ITGB2
  22q11.21(22127160--22153507)            1        26,347        MAPK1
  22q11.23(23523722--23524530)            1        808           BCR
  22q13.2(41574270--42526792)             4        952,522       EP300:CYP2D6
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![Sagittal T1-weighted magnetic resonance images depict focuses of plasma cell infiltration and pathologic fractures in the T4 (**A**) and L1 (**B**) vertebrae.\
**Note:** Red arrows indicate large focal lesions in the vertebrae.](ott-8-2805Fig1){#f1-ott-8-2805}

![Evaluation of a bone marrow aspirate.\
**Notes:** (**A**) Conventional karyotyping of metaphase cells from BM aspirate was performed using the G-banding technique. Complex cytogenetic aberrancies including loss of chromosomes, and additional uncharacterized materials at chromosome 8 (1) and 13 (2) are shown here. In addition, a dicentric translocation involving chromosome 11 and 14 (3) were also observed. (**B**) Visualization of CNVs over the entire genome in the karyotype view. The decreased copy number is indicated in red with increased copy number indicated in blue. (**C**) Interphase FISH studies were performed on BM aspirates using IgH/CCND1 dual color dual fusion probe (Vysis Inc., Des Plaines, IL, USA). The cell showed one orange (normal CCND1), one green (normal IgH), and two yellow signals (arrows), indicating typical t(11;14) rearrangement.\
**Abbreviations:** CNV, copy number variant; FISH, fluorescence in situ hybridization; BM, bone marrow.](ott-8-2805Fig2){#f2-ott-8-2805}

![Clinical course of the patient.\
**Abbreviations:** HD, high dose; DEX, dexamethsone; Cy, cyclophosphamide; FLC, free light chain; IgG, Immunoglobulin G.](ott-8-2805Fig3){#f3-ott-8-2805}

###### 

Somatic mutations identified in our case

  Gene      Function              Exon   Protein        Coding            Total coverage   Variant coverage   Variant frequency (%)
  --------- --------------------- ------ -------------- ----------------- ---------------- ------------------ -----------------------
  *SYNE1*   Missense              60     p.Val3187Gly   c.9560T\>G        68               11                 16.2
  *EGFR*    Frameshift deletion   13     p.Glu513Gly    c.1538_1539delG   235              218                92.8
  *IKBK*B   Missense              9      p.Val241Glu    c.722T\>A         125              20                 16.0
  *ERBB3*   Missense              25     p.Thr1024Asn   c.3071C\>A        158              47                 29.7
  *MYH11*   Missense              8      p.Ala275Gly    c.824C\>G         70               15                 21.4
  *CYLD*    Missense              18     p.Cys791Arg    c.2371T\>C        25               15                 60.0
  *TP53*    Missense              5      p.Arg158Gly    c.472C\>G         79               71                 89.9
  *CDH2*    Missense              16     p.Asp906Glu    c.2718C\>G        86               16                 18.6

**Notes:** List of total coverage, variant read coverage, and variant frequencies of somatic mutations identified in DNA isolated from BM aspirates of this case. BM mononuclear cells were separated using Ficoll--Paque density sedimentation, and plasma cells were purified by positive selection with anti-CD138 magnetic-activated cell separation microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Somatic mutations were detected using statistical approaches in tumor (CD138 positive) and normal (CD138 negative) samples from the Ion Reporter software 4.0 tumor-normal workflow. A sequencing coverage of 25× and a minimum variant frequency of 15% of the total number of distinct tags were used as cutoffs. Mutations were called if they occurred in \<1% of reads in the normal control, and were absent from dbSNP and the 1,000 Genomes Project database.

**Abbreviation:** BM, bone marrow.

###### 

Nucleotide variants identified in CD138-negative bone marrow aspirates from our case-1

  Locus number     Coverage   Variant coverage   Frequency (%)   Gene       Function   Exon   Protein        Coding        dbsnp[a](#tfn4-ott-8-2805){ref-type="table-fn"}
  ---------------- ---------- ------------------ --------------- ---------- ---------- ------ -------------- ------------- -------------------------------------------------
  chr2:219543924   155        67                 43.2            *STK36*    Missense   7      p.Arg240Trp    c.718C\>T     rs35038757
  chr3:14199887    189        101                53.4            *XPC*      Missense   9      p.Ala499Val    c.1496C\>T    rs2228000
  chr4:106155185   127        127                100.0           *TET2*     Missense   3      p.Pro29Arg     c.86C\>G      rs12498609
  chr4:1801064     158        60                 38.0            *FGFR3*    Missense   3      p.Gly65Arg     c.193G\>A     rs2305178
  chr4:1807488     100        48                 48.0            *FGFR3*    Missense   13     p.Val555Leu    c.1663G\>T    rs199544087
  chr4:55139771    328        155                47.3            *PDGFRA*   Missense   10     p.Ser478Pro    c.1432T\>C    rs35597368
  chr4:55981531    153        59                 38.6            *KDR*      Missense   4      p.Val136Met    c.406G\>A     rs35636987
  chr5:176637576   102        102                100.0           *NSD1*     Missense   5      p.Ser726Pro    c.2176T\>C    rs28932178
  chr5:256509      134        61                 45.5            *SDHA*     Missense   15     p.Val657Ile    c.1969G\>A    rs6962
  chr5:7878179     139        79                 56.8            *MTRR*     Missense   5      p.Ser202Leu    c.605C\>T     rs1532268
  chr6:152443756   115        60                 52.2            *SYNE1*    Missense   146    p.Gly8737Ser   c.26209G\>A   rs2295191
  chr6:32190390    150        148                98.7            *NOTCH4*   Missense   3      p.Lys117Gln    c.349A\>C     rs915894
  chr6:56351972    143        74                 51.7            *DST*      Missense   81     p.Leu4874Val   c.14620C\>G   rs80260070
  chr6:56417545    104        103                99.0            *DST*      Missense   55     p.Thr3230Ala   c.9688A\>G    rs4715631
  chr6:56463410    144        72                 50.0            *DST*      Missense   40     p.Gln1812Arg   c.5435A\>G    rs4712138
  chr7:6026988     140        67                 47.9            *PMS2*     Missense   11     p.Pro470Ser    c.1408C\>T    rs1805321
  chr7:91712698    220        101                45.9            *AKAP9*    Missense   33     p.Asn2792Ser   c.8375A\>G    rs6960867
  chr8:145741439   180        105                58.3            *RECQL4*   Missense   5      p.Arg355Gln    c.1064G\>A    rs374743591
  chr10:43610119   230        111                48.3            *RET*      Missense   11     p.Gly691Ser    c.2071G\>A    rs1799939
  chr10:70332672   226        117                51.8            *TET1*     Missense   2      p.Ser193Thr    c.577T\>A     rs12773594
  chr12:49431094   189        94                 49.7            *KMT2D*    Missense   34     p.Met3349Val   c.10045A\>G   rs80149580
  chr14:51224417   141        74                 52.5            *NIN*      Missense   18     p.Pro1111Ala   c.3331C\>G    rs2236316
  chr14:92460227   200        98                 49.0            *TRIP11*   Missense   15     p.Glu1696Lys   c.5086G\>A    rs80200454
  chr14:92472416   87         48                 55.2            *TRIP11*   Missense   11     p.Ser635Cys    c.1904C\>G    rs59635749
  chr15:40898643   173        77                 44.5            *CASC5*    Missense   4      p.Arg43Thr     c.128G\>C     rs7177192
  chr15:40913840   208        92                 44.2            *CASC5*    Missense   10     p.Ala460Ser    c.1378G\>T    rs2412541
  chr15:40914177   114        54                 47.4            *CASC5*    Missense   10     p.Met572Thr    c.1715T\>C    rs11858113
  chr15:40915190   148        78                 52.7            *CASC5*    Missense   10     p.Arg910Gly    c.2728A\>G    rs8040502
  chr15:40916632   173        78                 45.1            *CASC5*    Missense   10     p.Asp1390Glu   c.4170T\>A    rs141726041
  chr15:41805237   149        72                 48.3            *LTK*      Missense   2      p.Arg42Gln     c.125G\>A     rs2305030
  chr17:5462805    136        67                 49.3            *NLRP1*    Missense   4      p.Arg404Gln    c.1211G\>A    rs3744718
  chr18:47800179   147        61                 41.5            *MBD1*     Missense   12     p.Pro401Ala    c.1201C\>G    rs125555
  chr18:50832072   125        73                 58.4            *DCC*      Missense   13     p.Leu679Arg    c.2036T\>G    rs2271042
  chr19:18876309   106        52                 49.1            *CRTC1*    Missense   10     p.Thr344Ala    c.1030A\>G    rs3746266

**Notes:** DNA was extracted from CD138-negative BM aspirates of this case and peripheral blood of healthy donor-1 (TT) using the QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany) following manufacturer's instructions. DNA (40 ng) was used for multiplex PCR amplification with an Ion Ampliseq Comprehensive Cancer Panel (Life Technologies, Carlsbad, CA,USA), enabling the targeted coverage of all exons of 409 cancer-related genes in a 4-tube reaction (covered regions =95.4% of total). Nucleotide variants on the CD138-negative BM aspirates of this case were detected using the peripheral blood of healthy donor-1 as a normal control. A sequencing coverage of 25× and a minimum variant frequency of 15% of the total number of distinct tags were used as cutoffs.

dbSNP ID number.

**Abbreviations:** BM, bone marrow; PCR, polymerase chain reaction.

###### 

Nucleotide variants identified in CD138 negative bone marrow aspirates from our case-2

  Locus number     Coverage   Variant coverage   Frequency (%)   Gene        Codon      Exon   Protein        Coding        dbsnp[a](#tfn7-ott-8-2805){ref-type="table-fn"}
  ---------------- ---------- ------------------ --------------- ----------- ---------- ------ -------------- ------------- -------------------------------------------------
  chr1:114948281   64         63                 98.4            *TRIM33*    Missense   15     p.Ile840Thr    c.2519T\>C    rs6537825
  chr1:144879485   120        28                 23.3            *PDE4DIP*   Missense   27     p.Thr1322Arg   c.3965C\>G    rs113467089
  chr1:206665052   136        68                 50.0            *IKBKE*     Missense   18     p.Ala602Val    c.1805C\>T    rs12059562
  chr1:226555302   223        119                53.4            *PARP1*     Missense   17     p.Val762Ala    c.2285T\>C    rs1136410
  chr2:219543924   155        67                 43.2            *STK36*     Missense   7      p.Arg240Trp    c.718C\>T     rs35038757
  chr4:1801064     158        60                 38.0            *FGFR3*     Missense   3      p.Gly65Arg     c.193G\>A     rs2305178
  chr4:1807488     100        48                 48.0            *FGFR3*     Missense   13     p.Val555Leu    c.1663G\>T    rs199544087
  chr4:55139771    328        155                47.3            *PDGFRA*    Missense   10     p.Ser478Pro    c.1432T\>C    rs35597368
  chr4:55981531    153        59                 38.6            *KDR*       Missense   4      p.Val136Met    c.406G\>A     rs35636987
  chr5:256509      134        61                 45.5            *SDHA*      Missense   15     p.Val657Ile    c.1969G\>A    rs6962
  chr5:38496637    214        94                 43.9            *LIFR*      Missense   13     p.Asp578Asn    c.1732G\>A    rs3729740
  chr5:7878179     139        79                 56.8            *MTRR*      Missense   5      p.Ser202Leu    c.605C\>T     rs1532268
  chr6:152443756   115        60                 52.2            *SYNE1*     Missense   146    p.Gly8737Ser   c.26209G\>A   rs2295191
  chr6:51890823    157        87                 55.4            *PKHD1*     Missense   32     p.Ala1262Val   c.3785C\>T    rs9296669
  chr6:51914956    104        52                 50.0            *PKHD1*     Missense   22     p.Arg760Cys    c.2278C\>T    rs9370096
  chr6:56351972    143        74                 51.7            *DST*       Missense   81     p.Leu4874Val   c.14620C\>G   rs80260070
  chr6:56417282    157        157                100.0           *DST*       Missense   55     p.Met3317Ile   c.9951G\>A    rs4715630
  chr6:56417545    104        103                99.0            *DST*       Missense   55     p.Thr3230Ala   c.9688A\>G    rs4715631
  chr7:106509331   138        63                 45.7            *PIK3CG*    Missense   2      p.Ser442Tyr    c.1325C\>A    rs17847825
  chr8:145741439   180        105                58.3            *RECQL4*    Missense   5      p.Arg355Gln    c.1064G\>A    rs374743591
  chr9:8518052     124        67                 54.0            *PTPRD*     Missense   21     p.Gln447Glu    c.1339C\>G    rs10977171
  chr10:43610119   230        111                48.3            *RET*       Missense   11     p.Gly691Ser    c.2071G\>A    rs1799939
  chr12:49431094   189        94                 49.7            *KMT2D*     Missense   34     p.Met3349Val   c.10045A\>G   rs80149580
  chr14:51202311   140        69                 49.3            *NIN*       Missense   28     p.Gln1934Glu   c.5800C\>G    rs2295847
  chr14:92460227   200        98                 49.0            *TRIP11*    Missense   15     p.Glu1696Lys   c.5086G\>A    rs80200454
  chr14:92472416   87         48                 55.2            *TRIP11*    Missense   11     p.Ser635Cys    c.1904C\>G    rs59635749
  chr15:39880822   330        157                47.6            *THBS1*     Missense   10     p.Thr523Ala    c.1567A\>G    rs2292305
  chr15:40914177   114        54                 47.4            *CASC5*     Missense   10     p.Met572Thr    c.1715T\>C    rs11858113
  chr15:40916632   173        78                 45.1            *CASC5*     Missense   10     p.Asp1390Glu   c.4170T\>A    rs141726041
  chr15:41805237   149        72                 48.3            *LTK*       Missense   2      p.Arg42Gln     c.125G\>A     rs2305030
  chr16:15820863   305        305                100.0           *MYH11*     Missense   29     p.Ala1241Thr   c.3721G\>A    rs16967494
  chr18:47800179   147        61                 41.5            *MBD1*      Missense   12     p.Pro401Ala    c.1201C\>G    rs125555
  chr18:50832072   125        73                 58.4            *DCC*       Missense   13     p.Leu679Arg    c.2036T\>G    rs2271042
  chr22:42526694   112        76                 67.9            *CYP2D6*    Missense   1      p.Pro34Ser     c.100C\>T     rs1065852

**Notes:** DNA was extracted from CD138 negative BM aspirates of this case and peripheral blood of healthy donor 2 (Y.S.) using the QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany) following manufacturer's instructions. DNA (40 ng) was used for multiplex PCR amplification with an Ion Ampliseq Comprehensive Cancer Panel (Life Technologies, Carlsbad, CA, USA), enabling the targeted coverage of all exons of 409 cancer-related genes in a four tube reaction (covered regions =95.4% of total). Nucleotide variants on the CD138-negative BM aspirates of this case were detected using the peripheral blood of healthy donor-2 as a normal control. A sequencing coverage of 25× and a minimum variant frequency of 15% of the total number of distinct tags were used as cutoffs.

dbSNP ID number.

**Abbreviations:** BM, bone marrow; PCR, polymerase chain reaction.
